Conatus Pharmaceut (NASDAQ: CNAT) reported Q2 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40).

Program Updates

Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease and acute exacerbations of chronic liver disease, including:

• Patients with acute-on-chronic liver failure (ACLF);
• Patients with chronic liver failure (CLF);
• Post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR); and
• Patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).

For earnings history and earnings-related data on Conatus Pharmaceut (CNAT) click here.